Sort
46,585 grants matching “heart failure”
ENGLISH LONGITUDINAL STUDY OF AGING
$1,253,743University College London · R01 · FY2004 · AG
The role of PKD proteins in regulating tubular morphology
$1,253,689Gregory Germino · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2017 · DK
RESEARCH RESOURCE FOR COMPLEX PHYSIOLOGIC SIGNALS
$1,252,091Beth Israel Deaconess Medical Center · P41 · FY2003 · RR
Improving Long-Term Outcomes Clinical Research for Acute Respiratory Failure
$1,251,140Dale Murray Needham · Johns Hopkins University · R24 · FY2014 · HL
Stem cells for therapeutics discovery in genetic blood disorders
$1,251,085George Q Daley · Boston Children'S Hospital · U01 · FY2019 · HL
Data Coordinating Center for IMMEDIATE Trial
$1,251,007Tufts Medical Center · U01 · FY2005 · HL
Autonomic Rare Diseases Clinical Research Consortium
$1,250,002David Herlie Robertson · Vanderbilt University · U54 · FY2015 · NS
Autonomic Rare Diseases Clinical Research Consortium
$1,250,001Italo Biaggioni · Vanderbilt University Medical Center · U54 · FY2017 · NS
Autonomic Rare Diseases Clinical Research Consortium
$1,250,001Italo Biaggioni · Vanderbilt University Medical Center · U54 · FY2018 · NS
Autonomic Rare Diseases Clinical Research Consortium
$1,250,001David Herlie Robertson · Vanderbilt University Medical Center · U54 · FY2016 · NS
Clinical and Translational Science Award
$1,250,000Reza Shaker · Medical College Of Wisconsin · UL1 · FY2021 · TR
Clinical Trials Network: Long Island Regional Node
$1,250,000Edward V Nunes · New York State Psychiatric Institute Dba Research Foundation For Mental Hygiene, Inc · U10 · FY2007 · DA
Safety, tolerability and efficacy of a novel sustained release analog of vasoactive intestinal peptide, PB1046, in patients with pulmonary arterial hypertension
$1,249,307John Lee · Phasebio Pharmaceuticals, Inc. · R44 · FY2019 · HL
San Diego EXPORT Comprehensive NCMHD Research Center
$1,249,184Sandra P Daley · University Of California, San Diego · P60 · FY2009 · MD
ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES FOLLOW-ON (ACCORDION) STUDY- C
$1,249,058Robert Byington · Wake Forest University Health Sciences · N01 · FY2013 · HL
New chemotherapy regimens and biomarkers for Chagas disease
$1,248,620Igor C Almeida · University Of Texas El Paso · U01 · FY2020 · AI
Safety, tolerability and efficacy of a novel sustained release analog of vasoactive intestinal peptide, PB1046, in patients with pulmonary arterial hypertension
$1,247,966John Lee · Phasebio Pharmaceuticals, Inc. · R44 · FY2018 · HL
Development of an Innovative Material for Transcatheter Peripheral Embolization
$1,247,814Ehsan Jabbarzadeh · Obsidio, Inc. · R44 · FY2022 · HL
CHS Events Follow-up Study
$1,247,777Bruce M Psaty · University Of Washington · R01 · FY2010 · HL
Monetary incentives and intrinsic motivation to sustain hypertension control
$1,247,695Martin F Shapiro · University Of California Los Angeles · RC4 · FY2010 · AG
Highly sensitive measurement of cTnI without a reader: the Xip solution
$1,247,400Rajinder Bhatia · Silicon Biodevices, Inc. · R44 · FY2017 · HL
Spatial Resynchronization Therapy for AFib
$1,247,262Graydon Ernest Beatty · Maxwell Biomedical Inc · R44 · FY2025 · HL
Diabetes and Heart Disease Risk in Blacks
$1,246,870Anne Sumner · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2023 · DK
PERSEVERE-PEF: optimizing medical therapy saves lives in heart failure with preserved ejection fraction
$1,246,428Gabriela Voskerician · Optima Integrated Health, Inc. · R44 · FY2023 · HL
Genetic contributors to diabetes and dyslipidemia in African Americans
$1,245,341Michele M Sale · University Of Virginia · R01 · FY2010 · DK